← Leaderboards

George L King

Joslin Diabetes Center

Google Scholar ↗PubMed ↗ORCID ↗

$33,057,965

Attributed

$34,120,846

Total exposure

25

Grants

17

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.7M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$54,367,256 · 26

By mechanism

P30$23,570,860 · 6

R01$18,265,896 · 8

DP3$6,366,331 · 2

R24$2,183,168 · 2

U01$2,029,432 · 1

R21$1,189,833 · 3

Top collaborators

Andrzej S Krolewski3 shared
Amy Jo Wagers1 shared

Most similar at Joslin Diabetes Center

Same institution · by research overlap

Lloyd P Aiello$1,714,136

Others in their field

Top investigators on “Diabetes Mellitus”

Jeffrey P Krischer · University Of South Florida$608,226,434
Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
John M Lachin · George Washington University$155,262,668
David M Nathan · Massachusetts Institute Of Technology$142,806,023
Judith S Hochman · New York University School Of Medicine$100,149,457
Jose A Luchsinger · Columbia University Health Sciences$75,551,718

Research focus

Diabetes MellitusCellsHyperglycemiaBaseClinical ResearchDiabeticBlood VesselsLaboratoriesAffectVascular Endothelial Growth FactorsReportingResearch PersonnelInsulinTechnologyGlucoseAreaAnimalsPathway InteractionsServicesProgramsEndothelial CellsProtein Kinase CTissuesInnovation

Grant awards (100)

Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes$1,020,124

U01 · FY2025 · DK · contact PI

Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes$758,888

R01 · FY2025 · HL · contact PI

Characterization of risk factors for excessive cardiovascular diseases (CVD) from circulating and cardiovascular tissues of people with well-controlled chronic type 1 diabetes$1,009,308

U01 · FY2024 · DK · contact PI

Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes$774,662

R01 · FY2024 · HL · contact PI

Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration$471,383

R01 · FY2024 · EY · contact PI

Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes$775,846

R01 · FY2023 · HL · contact PI

Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration$479,838

R01 · FY2023 · EY · contact PI

A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes$213,125

R21 · FY2023 · MD · contact PI

Diabetes Research Center$1,698,590

P30 · FY2022 · DK · contact PI

Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes$850,868

R01 · FY2022 · HL · contact PI

Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration$465,441

R01 · FY2022 · EY · contact PI

A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes$255,563

R21 · FY2022 · MD · contact PI

Administrative Core$242,656

P30 · FY2022 · DK · contact PI

Diabetes Research Center$1,606,303

P30 · FY2021 · DK · contact PI

Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration$474,768

R01 · FY2021 · EY · contact PI

Administrative Core$158,716

P30 · FY2021 · DK · contact PI

Diabetes Research Center$1,628,165

P30 · FY2020 · DK · contact PI

Characterization of cognitive decline and Alzheimer's disease in long duration Type 1 diabetes$441,353

P30 · FY2020 · DK · contact PI

Administrative Core$158,716

P30 · FY2020 · DK · contact PI

Diabetes Research Center$77,802

P30 · FY2020 · DK · contact PI

Diabetes Research Center$1,646,953

P30 · FY2019 · DK · contact PI

Administrative Core$158,480

P30 · FY2019 · DK · contact PI

Diabetes Research Center$77,572

P30 · FY2019 · DK · contact PI

Diabetes Research Center$1,660,111

P30 · FY2018 · DK · contact PI

Identification of Retinoid-Binding Protein 3 (RBP3): A Protective Factor against Diabetic Retinopathy Using Retina from People with Extreme Duration of Diabetes$413,750

R01 · FY2018 · EY · contact PI

Administrative Core$157,777

P30 · FY2018 · DK · contact PI

Diabetes Research Center$1,667,502

P30 · FY2017 · DK · contact PI

Identification of Retinoid-Binding Protein 3 (RBP3): A Protective Factor against Diabetic Retinopathy Using Retina from People with Extreme Duration of Diabetes$413,750

R01 · FY2017 · EY · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$368,238

R01 · FY2017 · DK · contact PI

Administrative Core$156,602

P30 · FY2017 · DK · contact PI

Pyruvate kinase M2 levels and activation as protective factors for diabetic nephropathy$2,272,183

DP3 · FY2016 · DK · contact PI

Diabetes Research Center$1,919,986

P30 · FY2016 · DK · contact PI

Identification of Retinoid-Binding Protein 3 (RBP3): A Protective Factor against Diabetic Retinopathy Using Retina from People with Extreme Duration of Diabetes$413,750

R01 · FY2016 · EY · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$368,238

R01 · FY2016 · DK · contact PI

Aministrative Core$232,426

P30 · FY2016 · DK · contact PI

Diabetes Research Center$1,919,986

P30 · FY2015 · DK · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$368,238

R01 · FY2015 · DK · contact PI

Aministrative Core$219,294

P30 · FY2015 · DK · contact PI

Validation of Potential Protective Factors from Diabetic Complications$130,510

DP3 · FY2015 · DK · contact PI

Diabetes Research Center$1,919,986

P30 · FY2014 · DK · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$368,887

R01 · FY2014 · DK · contact PI

Aministrative Core$232,426

P30 · FY2014 · DK · contact PI

Diabetes Research Center$1,809,798

P30 · FY2013 · DK · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$333,252

R01 · FY2013 · DK · contact PI

Aministrative Core$218,275

P30 · FY2013 · DK · contact PI

Diabetes Research Center$1,740,994

P30 · FY2012 · DK · contact PI

Diabetes Research Center$431,309

P30 · FY2012 · DK · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$345,339

R01 · FY2012 · DK · contact PI

Aministrative Core$259,822

P30 · FY2012 · DK · contact PI

Protective Factors Against the Development of Microvascular Complications$235,395

R24 · FY2012 · DK · contact PI

Validation of Potential Protective Factors from Diabetic Complications$3,963,638

DP3 · FY2011 · DK · contact PI

Protective Factors Against the Development of Microvascular Complications$801,557

R24 · FY2011 · DK · contact PI

Cell Biology of Diabetic Microvascular Complications$394,416

R01 · FY2011 · EY · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$345,339

R01 · FY2011 · DK · contact PI

ANIMAL PHYSIOLOGY CORE$160,767

P30 · FY2011 · DK · contact PI

Protective Factors Against the Development of Microvascular Complications$816,608

R24 · FY2010 · DK · contact PI

Cell Biology of Diabetic Microvascular Complications$410,850

R01 · FY2010 · EY · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$384,912

R01 · FY2010 · DK · contact PI

ANIMAL PHYSIOLOGY CORE$181,881

P30 · FY2010 · DK · contact PI

Cell Biology of Diabetic Microvascular Complications$415,000

R01 · FY2009 · EY · contact PI

Selective Insulin Resistance- Diabetic Cardiovascular Diseases$388,100

R01 · FY2009 · DK · contact PI

Biomarkers for protection against complications and beta-cell destruction$329,608

R24 · FY2009 · DK · contact PI

ANIMAL PHYSIOLOGY CORE$166,121

P30 · FY2009 · DK · contact PI

Cell Biology of Diabetic Microvascular Complications$406,700

R01 · FY2008 · EY · contact PI

ANIMAL PHYSIOLOGY CORE$161,859

P30 · FY2008 · DK · contact PI

Cell Biology of Diabetic Microvascular Complications$415,000

R01 · FY2007 · EY · contact PI

PKC Activation and Cardiovascular Disease in Diabetes$393,495

R01 · FY2007 · DK · contact PI

Selective Insulin Resistance - Diabetic Vascular Disease$347,193

R01 · FY2007 · DK · contact PI

ANIMAL PHYSIOLOGY CORE$136,925

P30 · FY2007 · DK · contact PI

INFLAMMATORY RESPONSE TO DIETS BETWEEN ASIANS AND CAUCASIANS$4,697

M01 · FY2007 · RR · contact PI

PKC Activation and Cardiovascular Disease in Diabetes$405,248

R01 · FY2006 · DK · contact PI

Selective Insulin Resistance - Diabetic Vascular Disease$357,659

R01 · FY2006 · DK · contact PI

PKC Activation and Cardiovascular Disease in Diabetes$128,650

R01 · FY2006 · DK · contact PI

INFLAMMATORY RESPONSE TO DIETS BETWEEN ASIANS AND CAUCASIANS$7,039

M01 · FY2006 · RR · contact PI

PKC Activation and Cardiovascular Disease in Diabetes$415,500

R01 · FY2005 · DK

Selective Insulin Resistance - Diabetic Vascular Disease$366,364

R01 · FY2005 · DK

ANIMAL RESOURCES FACILITY EQUIPMENT IMPROVED PROJECT$650,000

G20 · FY2004 · RR

PKC Activation and Cardiovascular Disease in Diabetes$418,166

R01 · FY2004 · DK

PROTEIN KINASE C ACTIVATION AND DIABETIC CARDIOMYOPATHY$416,250

R01 · FY2004 · DK

Selective Insulin Resistance - Diabetic Vascular Disease$366,458

R01 · FY2004 · DK

PROTEIN KINASE C ACTIVATION AND DIABETIC CARDIOMYOPATHY$416,250

R01 · FY2003 · DK

Monocyte VEGF &PKC, Markers for Diabetic Complications$204,488

R21 · FY2003 · DK

Retinal imaging tests for microvascular functions$148,695

R21 · FY2003 · DK

PROTEIN KINASE C ACTIVATION AND DIABETIC CARDIOMYOPATHY$416,250

R01 · FY2002 · DK

Monocyte VEGF &PKC, Markers for Diabetic Complications$203,561

R21 · FY2002 · DK

Retinal imaging tests for microvascular functions$164,401

R21 · FY2002 · DK

Enhanced Program for Human Subject Protection$100,000

S07 · FY2002 · RR

PROTEIN KINASE C ACTIVATION AND DIABETIC CARDIOMYOPATHY$416,250

R01 · FY2001 · DK

ENDOTHELIN EFFECTS ON RETINAL CELLS AND BLOOD FLOW$284,300

R01 · FY2001 · EY

CELL BIOLOGY APPROACH TO DIABETIC RETINOPATHY$281,550

R01 · FY2001 · EY

CORE--MEDIA FACILITY$123,636

P30 · FY2001 · DK

CORE--MEDIA FACILITY$0

P30 · FY2001 · DK

CORE--MEDIA FACILITY$0

P30 · FY2001 · DK

CORE--MEDIA FACILITY$0

P30 · FY2001 · DK

CORE--MEDIA FACILITY$0

P30 · FY2001 · DK

PROTEIN KINASE C ACTIVATION AND DIABETIC CARDIOMYOPATHY$416,250

R01 · FY2000 · DK

ENDOTHELIN EFFECTS ON RETINAL CELLS AND BLOOD FLOW$277,590

R01 · FY2000 · EY

CELL BIOLOGY APPROACH TO DIABETIC RETINOPATHY$275,238

R01 · FY2000 · EY

SELECTIVE INSULIN RESISTANCE--DIABETIC VASCULAR DISEASE$261,782

R01 · FY2000 · DK

CORE--MEDIA FACILITY$198,071

P30 · FY2000 · DK